Health
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040
PRESS RELEASE AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2040 THIS DECISION STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY PORTFOLIO WITH LONG-TERM PROTECTION FOR AN ADDITIONAL INDICATION WITH A HIGH UNMET MEDICAL NEED THE BIOMARKER PHASE 2 IN COOPERATION WITH AP-HP IS FULLY FUNDED Paris, December 22, 2025, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the United States Patent Of
About this update from Ab Science Sa
[{"type":"image","alt":"AB Science","displaySize":"","headline":null,"caption":"AB Science","className":"","disableSlideshowImg":false,"size":{"original":{"width":156,"height":160,"url":"https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AW2UM4sIueJ.X0XSJNjHhQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7964f89fed41da51df043a8d3708bbe2","width":156,"height":160}},"lazy":false},{"type":"text","content":"PRESS RELEASE","length":13,"tagName":"p"},{"type":"text","content":"AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2040 ","length":138,"tagName":"p"},{"type":"text","content":"THIS DECISION STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY PORTFOLIO WITH LONG-TERM PROTECTION FOR AN ADDITIONAL INDICATION WITH A HIGH UNMET MEDICAL NEED","length":155,"tagName":"p"},{"type":"text","content":"THE BIOMARKER PHASE 2 IN COOPERATION WITH AP-HP IS FULLY FUNDED","length":63,"tagName":"p"},{"type":"text","content":"Paris, December 22, 2025, 6pm CET","length":33,"tagName":"p"},{"type":"text","content":"AB Science SA (Euronext - FR0010557264 - AB) today announced that the United States Patent Office has formally granted a patent for methods of treating sickle cell disease (i.e., a medical use patent) using its lead compound masitinib, based on preclinical data. This new US patent (US12,472,164) ensures intellectual property protection for masitinib until November 2040.","length":372,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Masitinib : An innovation in sickle cell disease","length":48,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":48,"olType":false},{"type":"text","content":"Sickle cell disease (SCD) is a group of inherited red blood cell disorders, with masitinib being developed to treat the most severe forms of the disease, which account for approximately 65% of cases. Severe SCD poses a major public health challenge and often leads to early death. While SCD treatment can be curative through gene therapy (targeting the HbS mutation), this option remains extremely limited due to donor scarcity, unresolved safety challenges, and high costs. Standard treatment for SCD includes red blood cell transfusions and treatm...